Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Up 14.2%

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s stock price rose 14.2% during mid-day trading on Thursday . The company traded as high as GBX 1.60 ($0.02) and last traded at GBX 1.54 ($0.02). Approximately 12,736,362 shares traded hands during mid-day trading, an increase of 49% from the average daily volume of 8,574,797 shares. The stock had previously closed at GBX 1.35 ($0.02).

Hemogenyx Pharmaceuticals Stock Up 4.7 %

The company has a market cap of £22.46 million, a P/E ratio of -167.60 and a beta of 3.14. The business’s 50 day moving average price is GBX 1.31 and its 200-day moving average price is GBX 1.50. The company has a debt-to-equity ratio of 105.93, a current ratio of 3.33 and a quick ratio of 6.72.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.